Order results by:
| Issue | Title | |
| Vol 5, No 1 (2012) | PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION | Abstract similar documents |
| R. Yagudina, A. Kulikov, B. Misikova | ||
| "... Pharmacoeconomic evaluation of treatment of the second and third lines of multiple myeloma ..." | ||
| Vol 7, No 2 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD | Abstract similar documents |
| A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin | ||
| "... context of bendamustine in the first line of therapy of a multiple myeloma for for patients more senior 65 ..." | ||
| Vol 10, No 2 (2017) | PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA | Abstract similar documents |
| M. Yu. Frolov, O. V. Shatalova | ||
| "... with recurrent and refractory multiple myeloma (MM), who had received previous 1st and 2nd (bortezomib ..." | ||
| Vol 8, No 1 (2015) | BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD | Abstract similar documents |
| A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina | ||
| "... in the first line of therapy of a multiple myeloma for patients more senior 65 years old with clinical ..." | ||
| Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
| О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
| "... myeloma (MM) ineligible for high-dose chemotherapy (HDCT) with subsequent autologous hematopoietic stem ..." | ||
| Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
| N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
| "... . На второй и последующих линиях терапии возможно применение цетуксимаба, панитумумаба, а также нового ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| "... фармакоэкономического анализа применения нилотиниба, дазатиниба и бозутиниба во второй линии терапии ХМЛ с позиции ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
| A. U. Kulikov | ||
| "... . По полученным результатам, применение эрлотиниба в качестве второй линии терапии пациентов с ..." | ||
| Vol 16, No 3 (2023) | Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... НМРЛ, обеспечиваемых ингибиторами PD-1/PD-L1 во второй и третьей линиях терапии, препаратом ..." | ||
| Vol 14, No 2 (2021) | Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting | Abstract similar documents |
| E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov | ||
| "... effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| Vol 11, No 4 (2018) | Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach | Abstract similar documents |
| A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya | ||
| "... (вторая линия терапии) и смерть. При рассмотрении последовательностей линий терапии и наличии ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer | Abstract similar documents |
| N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov | ||
| "... комбинации с летрозолом в первой линии лечения с позиции российского здравоохранения. Материалы и методы ..." | ||
| Vol 10, No 2 (2017) | PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY | Abstract similar documents |
| A. V. Rudakova, S. A. Protsenko, I. A. Koroleva | ||
| "... . Стандартами химиотерапии НМРЛ первой линии являются платиносодержащие режимы. Оптимальный вариант второй линии ..." | ||
| Vol 6, No 2 (2013) | COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... качестве терапии первой линии пациентов, которым за последние 6 месяцев был поставлен диагноз хронический ..." | ||
| Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... тирозинкиназы – нилотиниба (Тасигна) и иматиниба (Гливек), для лечения в качестве терапии первой линии пациентов ..." | ||
| Vol 17, No 1 (2024) | Chemoreactome screening of aquacobalamin and heptamethyl ester of cyanoaquacobyrinic acid cytotoxic effects on tumor cells with experimental confirmation on BT-474 and A549 cell | Abstract similar documents |
| I. Yu. Torshin, M. V. Filimonova, O. A. Gromova, L. A. Maiorova, M. A. Sorokina, D. E. Frolova, A. N. Gromov, I. A. Reyer | ||
| "... опухолевых клеток человека, в т.ч. клеточных линий SNB19 (астроцитома), HCT116 (рак толстой кишки), HeLa ..." | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... » у взрослых пациентов с немелкоклеточным раком легкого (НМРЛ) в 1-й линии терапии. Материал и методы ..." | ||
| Vol 17, No 2 (2024) | Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... формой мантийноклеточной лимфомы, получавших ранее по крайней мере одну линию терапии. Материал и методы ..." | ||
| Vol 16, No 4 (2023) | Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma | Abstract similar documents |
| S. K. Zyryanov, K. V. Orlova | ||
| "... пролголимабом в первой линии и комбинированной терапии ингибиторами BRAF/MEK во второй линии против схемы ..." | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov | ||
| "... Целью настоящего исследования является фармакоэкономический анализ терапии ДГПЖ второй линии ..." | ||
| Vol 16, No 3 (2023) | Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... первой линии терапии метастатической или неоперабельной меланомы кожи с мутацией V600 в гене BRAF в ..." | ||
| Vol 16, No 2 (2023) | Key principles of drug therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| A. V. Zhuravlev, O. I. Knysh | ||
| "... случаях усилить ответ на лечение. Во второй линии терапии применяются следующие препараты: нилотиниб ..." | ||
| Vol 8, No 2 (2015) | ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA | Abstract similar documents |
| Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov | ||
| "... основе ингибиторов протеазы с последующей терапией препаратами второй линии на основе ненуклеозидных ..." | ||
| Vol 9, No 3 (2016) | HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE | Abstract similar documents |
| A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina | ||
| "... средства в качестве второй, третьей и четвертой линий терапии (после неэффективности метотрексата ..." | ||
| Vol 11, No 3 (2018) | Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review | Abstract similar documents |
| D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin | ||
| "... сравнении с ПИТРС второй линии окрелизумаб имеет сходную эффективность, но более благоприятный профиль ..." | ||
| Vol 10, No 3 (2017) | Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients | Abstract similar documents |
| N. K. Mazina, P. V. Mazin | ||
| "... второй линии терапии КРРПЖ после доцетаксела в российских условиях. Материалы и методы. Был проведен ..." | ||
| Online First | Antitumor effects of vitamin B12 in vitro, in vivo, in silico | Abstract similar documents |
| O. A. Gromova, D. E. Frolova, I. Yu. Torshin, M. V. Filimonova, M. A. Sorokina, I. A. Reyer, O. A. Limanova, L. E. Fedotova, L. A. Maiorova | ||
| "... клеточной модели in vitro использовались клетки линий BT-474 (карцинома протока молочной железы) и A549 ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... Актуальность. В последние десятилетия в качестве стандартного варианта лечения первой линии у ..." | ||
| Vol 11, No 4 (2018) | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer | Abstract similar documents |
| N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov | ||
| "... в первой линии терапии мКРРПЖ. Для каждого из 84 субъектов РФ (за исключением Ненецкого АО) он ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract similar documents |
| D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
| "... исследования сопоставлены активные платиносодержащие режимы химиотерапии первой линии немелкоклеточного рака ..." | ||
| Vol 16, No 4 (2023) | Development of approaches to the evaluation of pharmacotherapy effectiveness for chronic hepatitis C | Abstract similar documents |
| I. A. Narkevich, E. A. Tsitlionok | ||
| "... – установленный диагноз «хронический гепатит С». Анализу и сравнению подвергались схемы первой линии терапии, в ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... блокад (ВКБ), пациенты второй (контрольной) группы получали курс стандартной терапии (НПВС, миорелаксанты ..." | ||
| Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov | ||
| "... на 6,75; 10,42 и 17,38% в первый, второй и третий год соответственно применение лакосамида в качестве ..." | ||
| Vol 10, No 1 (2017) | CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS | Abstract similar documents |
| P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova | ||
| "... препаратов при распространенных/метастатических СМТ при назначении во 2-й и последующих линиях химиотерапии в ..." | ||
| Vol 17, No 1 (2024) | Assessing the awareness of doctors of various specialties in the treatment of osteoporosis | Abstract similar documents |
| V. A. Alekseeva, A. V. Krikova, Т. Yu. Filatova, E. V. Dmitrieva, A. V. Ovsyankin, E. S. Kuzminova | ||
| "... препараты первой линии для лечения заболевания. Заключение. Исследование показало, что врачи имеют ..." | ||
| Vol 7, No 3 (2014) | PROBLEMS OF OUTCOMES CHOICE FOR THE ASSESSMENT OF REHABILITATION PROGRAMS EFFICIENCY IN PATIENTS AFTER STROKE AND CRANIOCEREBRAL INJURY | Abstract similar documents |
| V. S. Dombrovskiy, V. V. Omelyanovskiy | ||
| "... первого ко второму визиту, а общие изменения степеней инвалидности при последнем визите значительно меньше ..." | ||
| Vol 15, No 2 (2022) | Strengthening medical rehabilitation services in health system: a situation analysis | Abstract similar documents |
| D. V. Blinov, A. G. Solopova, L. N. Sandzhieva, E. E. Achkasov, D. I. Korabelnikov, D. M. Ampilogova, S. M. Khlopkova | ||
| "... медорганизаций первой и второй групп для организации МР, ограничения второго этапа МР в стационарных условиях ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic | Abstract similar documents |
| Yu. Sh. Gushchina, А. Yu. Abramov, Y. J. Haitham | ||
| "... . В результате анализа стоимости схем второго и третьего рядов выявлено, что средняя стоимость терапии ..." | ||
| Vol 18, No 1 (2025) | Analysis of methotrexate use practice in patients with rheumatoid and psoriatic arthritis | Abstract similar documents |
| S. A. Doktorova, Yu. Yu. Grabovetskaya, A. V. Zuev, J. N. Aksenova-Sorokhtei, V. V. Rafalskiy | ||
| "... , в связи с чем метотрексат (МТ) является препаратом первой линии и характеризуется высокой ..." | ||
| Vol 17, No 4 (2024) | Development of a classification of anesthetic management methods and protocols for calculating financial costs | Abstract similar documents |
| D. V. Lukyantseva, J. A. Agafonova, V. V. Omelyanovskiy, S. A. Kovaleva, D. V. Fedyaev, I. N. Pasechnik, V. V. Schukin, D. S. Blinov, A. B. Abrosimov | ||
| "... анестезиологическое пособие. На втором этапе выполнялось структурное и финансовое наполнение технологических карт по ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... втором этапе произведено сравнение ICER, рассчитанного по единой методике для БВ при ЛХ и других ..." | ||
| Vol 8, No 4 (2015) | PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER | Abstract similar documents |
| D. A. Zhukov | ||
| "... эффект от иммунизации работников вакциной Пневмо 23 становится положительным, начиная со второго года ..." | ||
| Vol 10, No 1 (2017) | BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS | Abstract similar documents |
| E. A. Pyadushkina | ||
| "... клиническую практику с долями 3%, 4% и 7% в первый, второй и третий год приведет к суммарной экономии затрат ..." | ||
| Vol 12, No 2 (2019) | Concerning the “repression” of ω -3 polyunsaturated fatty acids by adepts of evidence-based medicine | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, Zh. D. Kobalava | ||
| "... описаний отдельных исследований, во-вторых, учет важнейших характеристик фармацевтических различных форм ω ..." | ||
| Vol 12, No 3 (2019) | Approaches to assessing the demand for medical personnel in the Russian Federation | Abstract similar documents |
| S. N. Tishkina , T. G. Alkhasov , D. V. Lukyantseva , T. P. Bezdenezhnykh | ||
| "... фактической численности и штатной численности. При втором – путем сравнения фактической численности и ..." | ||
| Vol 14, No 1 (2021) | History of controlled trials in medicine: real priorities are little-known. Report 1. Basic concepts, terms, and disciplines that use medical experiment: historical and philosophical sources | Abstract similar documents |
| A. N. Koterov, O. A. Tikhonova, L. N. Ushenkova, A. P. Biryukov | ||
| "... экспериментов, а во-вторых, цели ее прогноза не направлены на отдельного человека. В то же время и клиническая ..." | ||
| Vol 16, No 3 (2023) | Analysis of tariff agreements of the constituent entities of the Russian Federation: form and completeness of data presentation | Abstract similar documents |
| D. V. Fedyaev, F. S. Nikitin, T. N. Artamonova, S. A. Kovaleva, V. V. Omelyanovskiy | ||
| "... структуры ТС, во второй группе – представления ТС в открытом доступе. Различия связаны с информационным ..." | ||
| Vol 17, No 2 (2024) | Study of lithium carbonate and ascorbate proliferative properties on transplantable Lewis lung carcinoma metastasis model | Abstract similar documents |
| D. E. Frolova, I. Yu. Torshin, V. V. Rastashansky, M. V. Filimonova, O. A. Gromova | ||
| "... различных доз аскорбата лития (1 и 10 мг/кг/сут в расчете на элементный литий), а во второй – сравнение ..." | ||
| 1 - 50 of 59 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
